Concentra (CON) Q3 2026 Earnings Call Transcript

Concentra reported Q3 revenue of $622.1 million, up 8.6% year over year, while adjusted EBITDA rose 17.9% to $140.2 million and adjusted EBITDA margin expanded 178 bps to 22.5%. It raised 2026 revenue guidance to $2.36 billion–$2.38 billion and adjusted EBITDA guidance to $505 million–$510 million; the board also authorized a new $250 million share-repurchase program. Free cash flow declined to $32.2 million from $40.2 million, mainly due to working-capital timing and higher tax payments, while net leverage was 2.9x.

Analysis

CON’s key signal is operating leverage: visit growth and pricing are flowing through to higher margins, while management raised EBITDA guidance more sharply than the revenue range. That supports earnings momentum into year-end, but the 2026 margin expansion should not be extrapolated mechanically: management expects the current margin level to be sustainable, not the same pace of expansion. The November TSA expiry is a near-term execution test; verify in the next filings whether separation costs actually roll off and whether replacement systems or staffing costs absorb the savings.

For the next 1–3 months, state workers’ compensation fee schedules—many expected in December—are the main identifiable pricing catalyst. Employer-services strength may precede workers’ comp volume, but one quarter is insufficient to treat it as a durable leading signal. If that volume strength persists, it would improve the organic-growth case beyond the company’s long-run framework; if hiring weakens, this growth component could reverse before claims-based data confirms it.

The less-appreciated constraint is cash allocation: weaker quarterly cash conversion, $1.52B debt, and simultaneous buybacks, debt reduction, and expansion make capital returns less compelling than the headline authorization suggests. The $250M authorization is capacity, not a commitment. New York entry and de novos offer upside, but require proof of returns and ramp execution. Select Medical’s TSA revenue or cost exposure from expiry is unquantified; do not infer a material consolidated impact.

Trade: a measured long CON on weakness is reasonable for a 1–3 month catalyst window, contingent on fee schedules and post-TSA cost evidence; avoid chasing without valuation context. Thesis weakens if 2027 pricing falls below the long-run expectation, visits decelerate materially, or margins retreat as separation costs end.

Key Decisions for Investors

• Consider a measured long CON on pullbacks, sizing to tolerate a reversal in cyclical visit growth; reassess after December fee schedules and the first post-TSA reporting evidence.
• Track workers’ compensation fee schedules, employer-services visits, and organic growth separately. A sustained employer-services-to-workers’-comp progression would strengthen the medium-term thesis; one quarter alone is not confirmation.
• Do not treat the new buyback authorization as a near-term earnings catalyst. Monitor actual repurchases, free-cash-flow conversion, leverage progress toward 2.5x, and whether acquisitions compete with debt reduction.
• Falsify or reduce the long thesis if fee-schedule updates imply weaker pricing, visit growth materially slows, or post-TSA margins fail to hold near current levels; verify the cost bridge in filings rather than relying solely on adjusted results.